breast cancer, locally advanced and metastatic First-line ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC)

5072 Independent central review of clinical benefit rates in FIRST: a Phase II comparison of fulvestrant 500 mg with anastrozole 1 mg as first-line endocrine therapy for postmenopausal women with hormone receptor positive advanced breast cancer

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(09)70964-4 ◽

2009 ◽

Vol 7 (2) ◽

pp. 282 ◽

Cited By ~ 1

Author(s):

J.P.O. Lindemann ◽

J.F.R. Robertson ◽

M.J. Ellis ◽

Y. Menu ◽

E.J. Macpherson ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Endocrine Therapy ◽

Phase Ii ◽

Clinical Benefit ◽

Hormone Receptor ◽

Advanced Breast ◽

First Line ◽

Ribociclib + letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative advanced breast cancer (ABC) who received no prior therapy for advanced disease

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0036-1592812 ◽

2016 ◽

Vol 76 (10) ◽

Author(s):

EM Grischke ◽

A Nusch ◽

N Marschner ◽

W Abenhardt ◽

J Wilke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Advanced Disease ◽

Advanced Breast ◽

Prior Therapy ◽

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

Annals of Oncology ◽

10.1093/annonc/mdu009 ◽

2014 ◽

Vol 25 (4) ◽

pp. 808-815 ◽

Cited By ~ 87

Author(s):

H.S. Rugo ◽

K.I. Pritchard ◽

M. Gnant ◽

S. Noguchi ◽

M. Piccart ◽

...

Keyword(s):

Breast Cancer ◽

Adverse Events ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Time Course ◽

Advanced Breast ◽

The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial

Journal of Bone Oncology ◽

10.1016/j.jbo.2018.09.010 ◽

2019 ◽

Vol 14 ◽

pp. 100199 ◽

Cited By ~ 1

Author(s):

Peyman Hadji ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M. Kurbacher ◽

Frederik Marmé ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Mammalian Target Of Rapamycin ◽

Advanced Breast ◽

Phase Iiib ◽

The Impact

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer

Annals of Oncology ◽

10.1093/annonc/mdy155 ◽

2018 ◽

Vol 29 (7) ◽

pp. 1541-1547 ◽

Cited By ~ 148

Author(s):

G.N. Hortobagyi ◽

S.M. Stemmer ◽

H.A. Burris ◽

Y.S. Yap ◽

G.S. Sonke ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Advanced Breast ◽

Phase Iii ◽

First Line ◽

Phase Iii Trial ◽

Abstract P3-06-04: 4EVER: The impact of mTOR inhibition on bone health in postmenopausal women with hormone receptor positive (HR+) advanced breast cancer treated with everolimus (EVE) in combination with exemestane (EXE)

10.1158/1538-7445.sabcs14-p3-06-04 ◽

2015 ◽

Author(s):

Peyman Hadji ◽

Hans Tesch ◽

Oliver Stoetzer ◽

Thomas Decker ◽

Christian M Kurbacher ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Bone Health ◽

Hormone Receptor ◽

Advanced Breast ◽

Mtor Inhibition ◽

The Impact

Abstract P5-21-18: Subsequent treatment for postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer who received ribociclib + letrozole vs placebo + letrozole in the phase III MONALEESA-2 study

10.1158/1538-7445.sabcs17-p5-21-18 ◽

2018 ◽

Cited By ~ 1

Author(s):

KL Blackwell ◽

S Paluch-Shimon ◽

M Campone ◽

P Conte ◽

K Petrakova ◽

...

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Subsequent Treatment ◽

Advanced Breast ◽

Phase Iii ◽

Pharmacokinetic Profile of the Fulvestrant Loading Dose Regimen in Postmenopausal Women with Hormone Receptor–Positive Advanced Breast Cancer

Clinical Breast Cancer ◽

10.3816/cbc.2008.n.040 ◽

2008 ◽

Vol 8 (4) ◽

pp. 347-351 ◽

Cited By ~ 26

Author(s):

Peter McCormack ◽

Francisco Sapunar

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Postmenopausal Women ◽

Hormone Receptor ◽

Dose Regimen ◽

Pharmacokinetic Profile ◽

Advanced Breast ◽

Loading Dose ◽

Definition of First-Line Endocrine Therapy for Hormone Receptor–Positive Advanced Breast Cancer

Journal of Clinical Oncology ◽

10.1200/jco.2015.66.0803 ◽

2016 ◽

Vol 34 (16) ◽

pp. 1959-1960 ◽

Cited By ~ 2

Author(s):

Tomás Reinert ◽

Carlos H. Barrios

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Endocrine Therapy ◽

Hormone Receptor ◽

Advanced Breast ◽

First Line ◽

Definition Of

A meta-analysis of anastrozole in combination with fulvestrant in the first line treatment of hormone receptor positive advanced breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-013-2495-0 ◽

2013 ◽

Vol 138 (3) ◽

pp. 961-965 ◽

Cited By ~ 13

Author(s):

Pui San Tan ◽

Benjamin Haaland ◽

Alberto J. Montero ◽

Gilberto Lopes

Keyword(s):

Breast Cancer ◽

Advanced Breast Cancer ◽

Hormone Receptor ◽

Meta Analysis ◽

Advanced Breast ◽

Line Treatment ◽

First Line ◽

First Line Treatment